Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


Shares of clinical-stage biotechnology company Equillium, Inc. (EQ) are rising more than 12% Tuesday morning after the company announced that the FDA has provided positive feedback on the company's plans to evaluate its Coronavirus drug candidate.


RTTNews | Sep 15, 2020 10:11AM EDT

10:11 Tuesday, September 15, 2020 (RTTNews.com) - Shares of clinical-stage biotechnology company Equillium, Inc. (EQ) are rising more than 12% Tuesday morning after the company announced that the FDA has provided positive feedback on the company's plans to evaluate its Coronavirus drug candidate.

The company said it has successfully completed a pre-IND meeting with the FDA to start the study of Equillium's drug candidate, itolizumab (EQ001) for the treatment for hospitalized patients with COVID-19.

Equillium plans to submit an IND application to the FDA in October 2020 and start a global Phase 3 study during the fourth quarter of this year.

Equillium stock is currently trading at $6.74. It has traded in the range of $2.20- $27.05 in the last one year.

Read the original article on RTTNews ( https://www.rttnews.com/3128757/stock-alert-equillium-jumps-12-on-fda-s-positive-feedback.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC